Howard Herrmann

Howard Herrmann

Interventional cardiologist / Cardiologist
University of Pennsylvania - Philadelphia, United States of America

Latest contributions

Hotline - TAVI - Part 2

16 Nov 2025 – From PCR London Valves 2025

This session presents cutting-edge research comparing self-expanding and balloon-expandable valves in urgent and emergent TAVI settings, with a focus on small aortic annuli. It includes data from the NAVULTRA and LANDMARK trials, featuring novel biomimetic balloon-expandable valves and early feasibility studies that shed light on valve...

The Top Late-Breaking Trials - Part 2

16 Nov 2025 – From PCR London Valves 2025

This session presents the latest data from pivotal late-breaking trials in interventional cardiology. Highlights include one-year results from the ADALA trial, first-in-man use of the Vivasure PerQseal Elite for large hole arterial closure, two-year outcomes of the DragonFly system in China, six-month European outcomes, and insights...

TAVI - Head-to-head comparative studies

22 May 2025 – From EuroPCR 2025

Compare head-to-head outcomes of various TAVI devices through real-world registries and meta-analyses. This session provides insights into performance differences between self-expanding and balloon-expandable valves to inform clinical decision-making.

TAVI - Head-to-head comparative studies

Hotline TAVI 2: outcomes with new and established devices

21 May 2025 – From EuroPCR 2025

Review outcomes of new and established TAVI devices through pooled analyses and multicenter studies. Topics include comparisons of balloon-expandable valves, intra- versus supra-annular self-expanding valves, and insights from the ACURATE IDE and ACURATE prime studies.

Hotline TAVI 2: outcomes with new and established devices

Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis

21 May 2025 – From EuroPCR 2025

Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.

Patients with under-expanded valves faced higher risks...

ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis

Innovation and strategies in TAVI: design, data and directions for clinical practice

15 May 2024 – From EuroPCR 2024

Watch this session to explore considerations for TAVI implantation in small annuli, gain insights into future lifetime management, learn about the benefits of FX technology and clinical evidence beyond small annuli, and witness a live case procedure showcasing the innovation of FX plus. This session is...

Innovation and strategies in TAVI: design, data and directions for clinical practice

TAVI Hotline: new devices, new approaches

15 May 2024 – From EuroPCR 2024

TAVI Hotline: new devices, new approaches

Self-expanding versus balloon-expandable transcatheter aortic valve replacement in patients with small aortic annuli: Primary outcomes from the randomized SMART Trial

07 Apr 2024

Alessandro Sticchi interviews Howard C. Herrmann about the primary outcomes from the randomized SMART Trial which he presented at ACC.24 in Atlanta.

Patients with severe aortic stenosis and small aortic annuli, typically female and often underrepresented in clinical trials, are at risk for impaired valvular hemodynamics and associated...

Howard Herrmann

Author

Howard Herrmann
Alessandro Sticchi

Author

Alessandro Sticchi

Which valve for which patient? - Part 1: simple anatomy

17 May 2023 – From EuroPCR 2023

Explore this session to gain insights into the influence of valve design on hemodynamic performance and durability, understand its implications for risk factors associated with TAVI in bicuspid aortic valves, and grasp the relationship between valve design, implantation techniques, and the emergence of new conduction abnormalities...

Which valve for which patient? - Part 1: simple anatomy

Long-term valve performance for the next decade and beyond

17 May 2023 – From EuroPCR 2023

How can TAVI outcomes be made better for younger patients with longer life horizons? Check-out in this session where you also will be able to gain in the understanding of the structural challenges of providing TAVI services and see how innovation can contribute to optimal outcomes and...

TAVI in patients with long-life expectancy - LIVE case

16 May 2023 – From EuroPCR 2023

Watch the case of a 75-year-old male patient with history of TIA, symptomatic severe aortic stenosis with RBBB, and preserved LV function. The heart team's decision was to perform TAVI with PCI on LAD a few days before procedure.

First, a cerebral protection device (Sentinel) was implanted....

TAVI in patients with long-life expectancy